Pharmacological Treatment of Marijuana Dependence

大麻依赖的药物治疗

• 批准号: 6801206
• 负责人: MARGARET HANEY
• 金额: $ 27.67万
• 依托单位: NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-09-01 至 2009-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6801206
• 关键词: behavioral /social science research tag; bupropion; cannabinoid receptor; cannabinoids; clinical research; clinical trials; combination chemotherapy; drug /alcohol abstinence; drug abuse chemotherapy; drug addiction antagonist; drug adverse effect; drug interactions; drug screening /evaluation; drug withdrawal; human subject; human therapy evaluation; marijuana abuse; model design /development; naltrexone; patient oriented research; psychopharmacology; reinforcer; relapse /recurrence; self medication

DESCRIPTION (provided by applicant): It is estimated that 4.2% of the U.S. population is dependent on marijuana. Among those seeking treatment for their marijuana use, only a small percentage are able to achieve abstinence. During our previous funding period, we developed a laboratory model that identified medications that attenuate symptoms of marijuana withdrawal. The objective of this competing continuation is to refine our model to predict medications that decrease relapse to marijuana use, defined as the resumption of marijuana smoking after a period of abstinence. The underlying assumption of this proposal is that 1) dependence and withdrawal play a role in maintaining frequent marijuana use, and 2) attenuating either marijuana withdrawal or marijuana's positive reinforcing effects will decrease relapse. Aim #1. Develop a laboratory model of marijuana relapse. We hypothesize that abstinence will: (1) increase symptoms of withdrawal, (2) decrease the latency to self-administer marijuana, (3) increase the quantity of marijuana self-administered. Aim #2. Evaluate the ability of pharmacological interventions to decrease marijuana relapse by attenuating symptoms of marijuana withdrawal. Using this model, we will evaluate oral THC and nefazodone, which we have shown decrease symptoms of marijuana withdrawal. We hypothesize that both oral THC and nefazodone will: (1) dose-dependently increase the latency to self-administer marijuana, and (2) thus, dose-dependently decrease the quantity of marijuana self-administered following a period of marijuana abstinence. Aim #3. Evaluate the ability of pharmacological interventions to decrease marijuana use by attenuating marijuana's direct effects. We will evaluate the cannabinoid receptor antagonist, SR141716A. We hypothesize that SR will dose-dependently decrease the quantity of marijuana self-administered following a period of marijuana abstinence. Little is known about the factors contributing to the high relapse rates in marijuana treatment-seekers. The strength of this protocol lies in our utilization of a controlled laboratory setting to examine the interactive effects of medications on marijuana self-administration under conditions that model relapse. The data collected will provide information on the positive and negative reinforcing factors maintaining near-daily marijuana use, and will suggest more efficacious approaches to treating marijuana dependence.

描述（由申请人提供）： 据估计，美国4.2％的人口取决于大麻。在寻求的人中 使用大麻的治疗方法，只有一小部分能够实现戒酒。在以前的资金期间，我们开发了一种实验室模型，该模型确定了减轻大麻戒断症状的药物。这种竞争延续的目的是完善我们的模型，以预测减少大麻使用复发的药物，该药物被定义为一段时间后的大麻吸烟。该提案的基本假设是1）依赖性和戒断在维持频繁使用大麻中的作用，以及2）衰减大麻戒断或大麻的阳性增强作用会减少复发。目标＃1。开发大麻复发的实验室模型。我们假设禁欲将：（1）增加戒断的症状，（2）减少自我管理大麻的潜伏期，（3）增加大麻自我管理的数量。 目标＃2。评估药理干预措施减少大麻复发的能力 大麻戒断的症状减弱。使用此模型，我们将评估口服THC和 Nefazodone，我们已经显示出降低大麻戒断的症状。我们假设口服Thc和nefazodone都将：（1）剂量依赖性地增加了自助大麻的潜伏期，并且（2）因此，剂量依赖性地降低了大麻自我管理的数量，而大麻持续了一段时间。目标＃3。评估药理学干预措施通过衰减大麻的直接作用来减少大麻使用的能力。我们将评估大麻素受体拮抗剂SR141716A。我们假设SR将依赖于剂量降低一段大麻戒酒后自我管理的大麻数量。关于导致大麻治疗者高复发率的因素知之甚少。该协议的强度在于我们利用受控实验室环境来检查药物对大麻自我给药的交互作用，在模型复发的条件下。收集的数据将提供有关维持几乎每日大麻使用的正面和负面增强因素的信息，并将提出更有效的方法来治疗大麻依赖性。